Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors

Erik A. Nelson, Sarah R. Walker, Ellen Weisberg, Michal Bar-Natan, Rosemary Barrett, Laurie B. Gashin, Shariya Terrell, Josephine L. Klitgaard, Loredana Santo, Martha R. Addorio, Benjamin L. Ebert, James D. Griffin, David A. Frank

Blood (2011) 117 (12): 3421–3429.

https://doi.org/10.1182/blood-2009-11-255232

Published: 2011

Includes: Supplemental data

Journal Articles

AT9283, a Small Molecule Multi-Targeted Kinase Inhibitor with Potent Activity Against Aurora Kinase and STAT3 In Combination with Lenalidomide Results In Synergistic Anti-Myeloma Activity

Loredana Santo, MD, Teru Hideshima, MD, PhD, Diana Cirstea, MD, Madhavi L Bandi, PhD, Erik A Nelson, PhD, Hiroshi Ikeda, MD, Sonia Vallet, MD, Samantha Pozzi, MD, Kishan Patel, Gullu Gorgun, PhD, Naoya Mimura, MD, Claire Fabre, MD, Yiguo Hu, PhD, Dharminder Chauhan, PhD, Matthew S Squires, PhD, Nikhil C. Munshi, MD, Kenneth C. Anderson, MD, Noopur Raje, MD

Blood (2010) 116 (21): 2994.

https://doi.org/10.1182/blood.V116.21.2994.2994

Published: 2010

Journal Articles

Inhibition of Both Jak2 and STAT5 Enhances Toxicity to Myeloproliferative Cells.

Michal Bar-Natan, M.D, Erik A. Nelson, PhD, Sarah R. Walker, Ph.D., Rosemary Barrett, B.S., David A. Frank, MD, PhD

Blood (2009) 114 (22): 1905.

https://doi.org/10.1182/blood.V114.22.1905.1905

Published: 2009

Journal Articles

AT9283, a Small Molecule Multi-Targeted Kinase Inhibitor Induces Antimyeloma Activity Via Potent Aurora Kinase and STAT3 Inhibition.

Loredana Santo, M.D., Teru Hideshima, MD., Ph.D., Erik A. Nelson, Ph.D, Diana Cirstea, MD, Madhavi Bandi, Ph.D, Hiroshi Ikeda, MD, PhD, Gullu Gorgun, PhD, Sonia Vallet, MD., Samantha Pozzi, MD, Giulia Perrone, MD, Kishan Patel, Yiguo Hu, Ph.D, Matthew S Squires, Murray Yule, Elisabetta Calabrese, MD., Dharminder Chauhan, Ph.D, Nikhil C. Munshi, Kenneth C. Anderson, MD, Noopur Raje, MD.

Blood (2009) 114 (22): 3833.

https://doi.org/10.1182/blood.V114.22.3833.3833

Published: 2009

Journal Articles

Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3

Erik A. Nelson, Sarah R. Walker, Alicia Kepich, Laurie B. Gashin, Teru Hideshima, Hiroshi Ikeda, Dharminder Chauhan, Kenneth C. Anderson, David A. Frank

Blood (2008) 112 (13): 5095–5102.

https://doi.org/10.1182/blood-2007-12-129718

Published: 2008

Includes: Supplemental data

Journal Articles

Pimozide Inhibits STAT5 Signaling in Chronic Myelogenous Leukemia and Reduces the Viability of Both Imatinib Sensitive and Imatinib Resistant Cells.

Erik A. Nelson, PhD, Sarah R. Walker, Ph.D., Alicia Kepich, B.S., Shariya Terrell, B.S., Laurie Gashin, B.S., David A. Frank, M.D., Ph.D.

Blood (2007) 110 (11): 2953.

https://doi.org/10.1182/blood.V110.11.2953.2953

Published: 2007

Journal Articles

Nifuroxazide Inhibits STAT3 Function and Shows Potent Anti-Tumor Activity Against Multiple Myeloma.

Erik A. Nelson, PhD, Teru Hideshima, M.D. Ph.D, Laurie Gashin, Sarah R. Walker, B.S., Rebecca A. Lynch, B.S., Dharminder Chauhan, Ph.D., Kenneth C. Anderson, M.D., David A. Frank, M.D.,Ph.D.

Blood (2006) 108 (11): 3450.

https://doi.org/10.1182/blood.V108.11.3450.3450

Published: 2006

Journal Articles

IL-2 regulates FOXP3 expression in human CD4 + CD25 + regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo

Emmanuel Zorn, Erik A. Nelson, Mehrdad Mohseni, Fabrice Porcheray, Haesook Kim, Despina Litsa, Roberto Bellucci, Elke Raderschall, Christine Canning, Robert J. Soiffer, David A. Frank, Jerome Ritz

Blood (2006) 108 (5): 1571–1579.

https://doi.org/10.1182/blood-2006-02-004747

Published: 2006

Journal Articles

IL-2 Therapy Promotes the Expansion of Human CD4+CD25+ Regulatory T Cells and Selectively Upregulates the Expression of FOXP3 in T Cells In Vivo.

Emmanuel Zorn, PhD, Erik A. Nelson, PhD, Mehrdad Mohseni, MD, Despina Litsa, BSc, Haesook Kim, PhD, Roberto Bellucci, PhD, Fabrice Porcheray, PharmD, Christine Canning, MD, Robert J. Soiffer, MD, Jerome Ritz, MD

Blood (2005) 106 (11): 1257.

https://doi.org/10.1182/blood.V106.11.1257.1257

Published: 2005

Journal Articles

The amino terminal and E2F interaction domains are critical for C/EBPα-mediated induction of granulopoietic development of hematopoietic cells

Francesco D'Alo', Lisa M. Johansen, Erik A. Nelson, Hanna S. Radomska, Erica K. Evans, Pu Zhang, Claus Nerlov, Daniel G. Tenen

Blood (2003) 102 (9): 3163–3171.

https://doi.org/10.1182/blood-2003-02-0479

Published: 2003

NARROW

The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors

AT9283, a Small Molecule Multi-Targeted Kinase Inhibitor with Potent Activity Against Aurora Kinase and STAT3 In Combination with Lenalidomide Results In Synergistic Anti-Myeloma Activity

Inhibition of Both Jak2 and STAT5 Enhances Toxicity to Myeloproliferative Cells.

AT9283, a Small Molecule Multi-Targeted Kinase Inhibitor Induces Antimyeloma Activity Via Potent Aurora Kinase and STAT3 Inhibition.

Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3

Pimozide Inhibits STAT5 Signaling in Chronic Myelogenous Leukemia and Reduces the Viability of Both Imatinib Sensitive and Imatinib Resistant Cells.

Nifuroxazide Inhibits STAT3 Function and Shows Potent Anti-Tumor Activity Against Multiple Myeloma.

IL-2 regulates FOXP3 expression in human CD4 + CD25 + regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo

IL-2 Therapy Promotes the Expansion of Human CD4+CD25+ Regulatory T Cells and Selectively Upregulates the Expression of FOXP3 in T Cells In Vivo.

The amino terminal and E2F interaction domains are critical for C/EBPα-mediated induction of granulopoietic development of hematopoietic cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only